Rheumatoid Arthritis

You have full text access to this OnlineOpen article

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients

  1. Daniel Aletaha1,†,
  2. Julia Funovits1,
  3. Edward C. Keystone2,‡,
  4. Josef S. Smolen3,§,*

Article first published online: 28 SEP 2007

DOI: 10.1002/art.22943

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 10, pages 3226–3235, October 2007

Additional Information

How to Cite

Aletaha, D., Funovits, J., Keystone, E. C. and Smolen, J. S. (2007), Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis & Rheumatism, 56: 3226–3235. doi: 10.1002/art.22943

Author Information

  1. 1

    Medical University of Vienna, Vienna, Austria

  2. 2

    Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada

  3. 3

    Medical University of Vienna, and Hietzing Hospital Vienna, Austria

  1. †

    Dr. Aletaha has received consulting or speaker's honoraria (less than $10,000 each) from Abbott, Sanofi-Aventis, Schering-Plough, and Wyeth.

  2. ‡

    Dr. Keystone has received consulting fees and honoraria from Hoffmann-La Roche, speaker's fees from Abbott, and consulting fees from Amgen/Wyeth (more than $10,000 each).

  3. §

    Dr. Smolen has received consulting or speaker's honoraria (less than $10,000 each) from Abbott, Amgen, Centocor, Schering-Plough, Sanofi-Aventis, and Wyeth.

*Medical University of Vienna, Division of Rheumatology, Internal Medicine III, Waehringer Guertel 18-20, A-1090 Vienna, Austria

Publication History

  1. Issue published online: 28 SEP 2007
  2. Article first published online: 28 SEP 2007
  3. Manuscript Accepted: 29 JUN 2007
  4. Manuscript Received: 13 FEB 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (205K)

REFERENCES

  • 1
    Masi AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med 1983; 75: 16–26.
  • 2
    Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123–51.
  • 3
    Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854–60.
    Direct Link:
  • 4
    Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 13–22.
  • 5
    Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63: 221–5.
  • 6
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–17.
    Direct Link:
  • 7
    Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003; 48: 3039–45.
    Direct Link:
  • 8
    Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 Suppl 1: 24–9.
  • 9
    Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003; 62 Suppl 2:ii 94–6.
  • 10
    Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 Suppl 31: S178–85.
  • 11
    St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 2004; 50: 3432–43.
    Direct Link:
  • 12
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.
  • 13
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
    Direct Link:
  • 14
    Sokka T, Pincus T. Most patients receiving routine clinical care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology remission criteria. J Rheumatol 2003; 30: 1138–46.
  • 15
    Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade [review]. Arthritis Rheum 2003; 48: 3308–19.
    Direct Link:
  • 16
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 17
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34–40.
    Direct Link:
  • 18
    Aletaha D, Smolen JS. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1: 62–3.
  • 19
    Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986; 25: 44–9.
  • 20
    Van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis: towards development of a decision support system. J Rheumatol 1997; 24: 20–7.
  • 21
    Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  • 22
    Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702–10.
    Direct Link:
  • 23
    Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab inhibits radiographic progression regardless of disease activity at baseline and following treatment in patients with early active rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S231.
  • 24
    Aletaha D, Smolen JS, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784–92.
    Direct Link:
  • 25
    Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772–7.
    Direct Link:
  • 26
    Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002; 46: 906–12.
    Direct Link:
  • 27
    Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108–11.
  • 28
    Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al. The prognostic value of anti–cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–5.
    Direct Link:
  • 29
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11.
    Direct Link:
  • 30
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 31
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244–57.
  • 32
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796–806.
  • 33
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 34
    Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625–36.
    Direct Link:
  • 35
    Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944–7.
  • 36
    Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63: 675–80.
  • 37
    Molenaar ET, Voskuyl AE, Dijkmans BA. Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol 2002; 29: 267–70.
  • 38
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al, for the FIN- RACo Trial Group. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894–8.
    Direct Link:
  • 39
    Smolen JS, Han C, Bala M, van der Heijde D, Emery P, Bathon J, et al. Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S139.
  • 40
    Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I, for the BARFOT Study Group. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360–70.
    Direct Link:
  • 41
    Van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al, for the TEMPO Investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64: 1582–7.
  • 42
    Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006; 32: 9–44.
  • 43
    Van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21: 425–9.
  • 44
    Lian TY, Koh ET, TTSH RA study group, Kong KO. Clinical Disease Activity Index (CDAI) is a valid instrument for assessing disease activity amongst oriental early rheumatoid arthritis (ERA) patients [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S377–8.
  • 45
    Guedes LK, Kowalski SC, Laurindo IM. The new indices SDAI and CDAI in early arthritis: similar performance to DAS28 index [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S206–7.
  • 46
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244–57.
  • 47
    Felson D, Xie H, LaValley M, Derson J, Koch G, Wolfe F, et al. A proposed revision to the ACR20: the hybrid measure of ACR response. Arthritis Rheum 2007; 57: 193–202.
    Direct Link:
  • 48
    Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006; 33: 1243–6.
  • 49
    Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975–9.
  • 50
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381–90.
    Direct Link:
  • 51
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–9.
  • 52
    Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 Suppl 31: S209–10.
  • 53
    Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006; 332: 1080.
  • 54
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study. Arthritis Rheum 2005; 52: 1020–30.
    Direct Link:
View Full Article (HTML) Get PDF (205K)